An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination with Capecitabine for Progressive or Recurrent Metastatic Breast Cancer

The primary objective of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent metastatic breast cancer. The secondary objective of this study is to characterize the pharmacokinetic profile of TRC105 and capecitabine when given in combination as well as to evaluate TRC105 immunogenicity by measuring human antimurine (HAMA) and human antichimeric antibody (HACA) titers.

Study Number: 

I 162809

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail